NRx Pharma Gets FDA Expanded Access for Ketamine Protocol

FDA Grants NRx Pharmaceuticals Expanded Access

On June 22, 2026, NRx Pharmaceuticals announced that the FDA has granted its program an Expanded Access designation — a regulatory pathway also known as compassionate use. This allows eligible patients to receive an investigational treatment outside of a formal clinical trial, typically when no comparable approved alternatives exist and the patient faces a serious or life-threatening condition.

For those following the ketamine treatment landscape, this development matters because NRx Pharmaceuticals has built its psychiatric treatment programs around a protocol that uses ketamine as an acute bridging therapy. Their approach targets patients with bipolar depression and acute suicidal ideation: stabilize the patient rapidly with ketamine, then transition to an oral maintenance regimen — specifically their investigational drug NRX-101, a fixed-dose combination of D-cycloserine and lurasidone — to sustain that stabilization over time.

An FDA Expanded Access grant signals that the agency sees sufficient evidence of potential benefit and an acceptable safety profile to justify broader patient access before full approval. It is not an approval, but it is a meaningful regulatory acknowledgment that the program has cleared important thresholds.

Ketamine as a Bridge: Understanding NRx's Model

The architecture of NRx's protocol is instructive for anyone thinking about where oral ketamine fits in broader psychiatric care. Their clinical program has positioned intravenous ketamine not as the destination treatment, but as the acute stabilizer — a rapid-onset intervention designed to buy time and reduce immediate risk while a slower-acting oral therapy takes hold.

This bridging model reflects a real challenge in ketamine medicine that clinicians and patients encounter regularly: ketamine works fast, but its effects on mood and suicidal ideation are often short-lived without ongoing treatment. IV infusions can reduce acute suicidal thinking within hours, but the effect window typically spans days to weeks. That gap has driven significant interest in oral and sublingual ketamine formulations — including tablets and troches — as lower-intensity maintenance options that patients can use at home between clinical touchpoints.

NRx's approach takes a different angle, pairing the ketamine bridge with an oral non-ketamine medication for longer-term maintenance rather than relying on repeated ketamine dosing. Whether that model or an oral ketamine maintenance approach ultimately proves more practical and effective for different patient populations remains an open clinical question, but both directions acknowledge the same underlying reality: getting patients stable is only the first step.

What Expanded Access Actually Means for Patients

An FDA Expanded Access designation does not mean a drug is available at your nearest clinic tomorrow. Access under this pathway typically requires a physician to submit an individual patient request to the FDA, document that standard treatments have failed or are unavailable, and coordinate directly with the manufacturer to obtain the investigational product. The process has real friction, and availability varies based on the company's capacity and willingness to provide the product.

That said, Expanded Access grants have historically served as important signals ahead of formal approval. They allow real-world safety and efficacy data to accumulate outside the controlled trial setting, and they create pathways for patients in urgent need who cannot wait for full approval timelines — which in psychiatry can stretch years beyond when a treatment's benefits first become apparent in trials.

For patients currently using oral ketamine tablets or troches through telehealth or clinic-based programs, this development is less about immediate access and more about the broader regulatory environment around ketamine-adjacent psychiatric care. A major pharmaceutical company receiving FDA Expanded Access for a ketamine-inclusive protocol reinforces that the FDA continues to engage seriously with ketamine's role in treating severe, treatment-resistant mood disorders.

The Bigger Picture for Oral Ketamine Access

NRx's announcement arrives as the oral ketamine landscape itself continues to evolve. Compounded ketamine tablets and troches have become increasingly common in clinical practice, particularly since telehealth-prescribing platforms expanded access to at-home oral ketamine for treatment-resistant depression and anxiety disorders. These products occupy a legally and regulatorily distinct space from NRx's investigational program — they are compounded medications, not FDA-approved drugs — but they serve many of the same patients.

The ketamine field is watching several simultaneous developments: DEA and FDA guidance on telehealth prescribing of controlled substances, ongoing clinical data from compounded ketamine programs, and the eventual disposition of pipeline products like NRX-101. How those threads resolve over the next 12 to 24 months will shape whether patients have more or fewer options for oral and home-based ketamine treatment.

For now, NRx's Expanded Access grant is a forward-looking data point. It suggests the company's clinical case is strong enough to satisfy the FDA's threshold for broader patient access, which in turn increases the probability — though does not guarantee — a future approval application will receive a serious hearing. Patients and clinicians interested in ketamine-based treatment for severe depression and suicidality should watch how NRx's expanded access data accumulates and whether a New Drug Application follows.

The core lesson for oral ketamine users: this announcement reflects growing institutional and regulatory validation of ketamine's role in psychiatric care, even as the specific products and protocols involved remain distinct from what is currently available through licensed prescribers and compounding pharmacies.